TL;DR
This study reveals that Salvianolic acid C (SalC), a compound from traditional Chinese medicine, effectively reduces brain damage and improves neurological function in mice after ischemic stroke. It achieves this by dampening neuroinflammation, specifically by inhibiting the TLR4-TREM1-NF-κB signaling pathway in microglia, offering a promising new therapeutic avenue for early-stage stroke treatment.
What Problem Does This Paper Address?
Stroke, particularly ischemic stroke, is a leading cause of death and disability worldwide, imposing a significant burden on healthcare systems. While treatments like r-tPA exist, their effectiveness is limited by a narrow therapeutic window and a high risk of complications. The early stages of stroke are critical for patient prognosis and rehabilitation, yet effective interventions for this acute phase are scarce. Neuroinflammation, driven by immune cells like microglia, plays a crucial role in exacerbating ischemic injury. Specifically, the TLR4-TREM1-NF-κB pathway has been implicated in this inflammatory cascade. However, the precise mechanisms by which natural compounds might intervene in this early inflammatory response remain largely unexplored. This paper aims to bridge this gap by investigating SalC's potential to mitigate acute ischemic stroke by targeting microglial-mediated neuroinflammation.
Methods
The researchers employed a multi-pronged approach combining in vivo animal models, in vitro cell culture experiments, and advanced computational techniques.
- Animal Model: A transient middle cerebral artery occlusion (tMCAO) model was used in mice to mimic ischemic stroke. Different groups received SalC at varying doses, edaravone (a positive control), or saline.
- Histopathology and Viability Assays: TTC staining was used to quantify infarct volume, while H&E staining assessed general tissue damage. TUNEL assays were performed to measure neuronal apoptosis. Cell viability was assessed using CCK-8 assays in cell culture.
- RNA Sequencing (RNA-seq): Transcriptome sequencing was performed on brain tissues to identify differentially expressed genes (DEGs) between the model and treatment groups.
- Network Pharmacology: RNA-seq data was integrated with a cerebrovascular disease (CVD)-related gene database to construct a Cerebral Ischemia Disease (CID) network. Network analysis tools were used to identify key nodes and pathways. The Efficiency of Recovery Regulation (EoR) method and Network Topology and Transcriptomics based Approach (NTRA) were applied to evaluate drug effects and identify key genes.
- Molecular Validation: Key findings from network analysis were validated using qRT-PCR and Western blotting to measure gene and protein expression levels of specific targets (e.g., TREM1, TLR4, p-p65/p65).
- In Vitro Co-culture System: A co-culture system of BV2 (microglia) and HT22 (neuronal) cells was established to investigate the role of microglia-neuron interactions and the effect of SalC on oxygen-glucose deprivation/reoxygenation (OGD/R)-induced injury.
Datasets
The study utilized transcriptomic data generated from mouse brain tissues subjected to tMCAO and SalC treatment. This data was then integrated with existing cerebrovascular disease (CVD)-related gene databases for network construction. No new public benchmarks were introduced.
Key Insights and Ideas
- SalC as a Broad-Spectrum Modulator: The study suggests SalC doesn't just target one molecule but exerts a "multi-target mechanism" by influencing a large number of genes within the CID network, indicating a comprehensive therapeutic effect.
- Targeting the Early Inflammatory Cascade: The research pinpoints the TLR4-TREM1-NF-κB pathway as a critical target for SalC's neuroprotective effects, highlighting the importance of intervening in the initial inflammatory response.
- Microglia as a Key Player: The findings strongly implicate microglia as central mediators of SalC's action, with SalC specifically inhibiting TREM1 expression on these cells.
- Bridging In Vivo and In Vitro Findings: The study successfully links in vivo observations of reduced brain damage with in vitro experiments demonstrating SalC's protective effects on both neuronal and microglial cells under ischemic conditions.
Key Results
- Reduced Infarct Volume and Improved Neurological Function: SalC treatment significantly reduced infarct volume (e.g., from 30.9% in the model group to 15.5% and 10.9% with low and high doses, respectively) and improved neurological deficit scores in tMCAO mice.
- Histopathological Improvement: SalC treatment reversed pathological changes and reduced neuronal apoptosis in the ischemic brain tissue.
- Gene Expression Reversal: SalC treatment reversed approximately 80% of the dysregulated genes in the CID network, with over 53% showing more than 50% recovery efficiency.
- Inhibition of Neuroinflammatory Pathways: Pathway enrichment analysis identified neuroinflammation and TREM1 signaling as significantly affected by SalC. Specifically, SalC downregulated the expression of TREM1, TLR4, and phosphorylated p65 (a key component of NF-κB signaling) in both in vivo and in vitro models.
- Microglial TREM1 Inhibition: Immunofluorescence staining confirmed that SalC significantly decreased TREM1 expression in microglia within the ischemic penumbra.
- Protection Against OGD/R Injury: In cell culture, SalC significantly increased the survival rate of OGD/R-injured BV2 and HT22 cells, and its conditioned medium also protected HT22 cells from the detrimental effects of OGD/R-treated BV2 cells.
Limitations and Future Work
The authors acknowledge that understanding the interaction between peripheral and brain immune systems, which contributes to neuroinflammation and activates the TLR4-TREM1-NF-κB pathway, requires further investigation. Additionally, due to the heterogeneity of microglia, they suggest that employing single-cell sequencing technology is necessary for a more detailed elucidation of SalC's roles and effects. Future research could also explore the precise molecular mechanisms by which SalC interacts with the TLR4-TREM1-NF-κB pathway.
Summary updated